Why FDA Approval of Vepdegestrant Marks a Major Shift in Cancer Therapy
The U.S. Food and Drug Administration’s approval of vepdegestrant on 1 May for patients with ESR1-mutated, ER-positive and HER2-negative advanced breast cancer represents a landmark moment in pharmaceutical science, as it is the world’s first therapy built on PROTAC (proteolysis-targeting chimera) technology to receive regulatory clearance. Rather than merely blocking a harmful protein’s activity, as…